aTyr Pharma Statistics
Total Valuation
aTyr Pharma has a market cap or net worth of $94.05 million. The enterprise value is $16.20 million.
Important Dates
The next estimated earnings date is Tuesday, March 17, 2026, after market close.
| Earnings Date | Mar 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
aTyr Pharma has 97.99 million shares outstanding. The number of shares has increased by 30.37% in one year.
| Current Share Class | 97.99M |
| Shares Outstanding | 97.99M |
| Shares Change (YoY) | +30.37% |
| Shares Change (QoQ) | +7.80% |
| Owned by Insiders (%) | 2.50% |
| Owned by Institutions (%) | 55.62% |
| Float | 95.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 494.99 |
| Forward PS | n/a |
| PB Ratio | 1.17 |
| P/TBV Ratio | 1.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 85.29 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.93, with a Debt / Equity ratio of 0.15.
| Current Ratio | 5.93 |
| Quick Ratio | 5.82 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -103.49% and return on invested capital (ROIC) is -57.46%.
| Return on Equity (ROE) | -103.49% |
| Return on Assets (ROA) | -49.59% |
| Return on Invested Capital (ROIC) | -57.46% |
| Return on Capital Employed (ROCE) | -86.45% |
| Weighted Average Cost of Capital (WACC) | 6.56% |
| Revenue Per Employee | $2,923 |
| Profits Per Employee | -$1.16M |
| Employee Count | 65 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -75.20% in the last 52 weeks. The beta is 0.58, so aTyr Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.58 |
| 52-Week Price Change | -75.20% |
| 50-Day Moving Average | 0.82 |
| 200-Day Moving Average | 2.64 |
| Relative Strength Index (RSI) | 54.97 |
| Average Volume (20 Days) | 2,150,346 |
Short Selling Information
The latest short interest is 20.43 million, so 20.85% of the outstanding shares have been sold short.
| Short Interest | 20.43M |
| Short Previous Month | 21.33M |
| Short % of Shares Out | 20.85% |
| Short % of Float | 21.39% |
| Short Ratio (days to cover) | 9.57 |
Income Statement
In the last 12 months, aTyr Pharma had revenue of $190,000 and -$75.12 million in losses. Loss per share was -$0.84.
| Revenue | 190,000 |
| Gross Profit | -61.37M |
| Operating Income | -78.65M |
| Pretax Income | -75.13M |
| Net Income | -75.12M |
| EBITDA | -77.98M |
| EBIT | -78.65M |
| Loss Per Share | -$0.84 |
Full Income StatementBalance Sheet
The company has $90.20 million in cash and $12.36 million in debt, with a net cash position of $77.84 million or $0.79 per share.
| Cash & Cash Equivalents | 90.20M |
| Total Debt | 12.36M |
| Net Cash | 77.84M |
| Net Cash Per Share | $0.79 |
| Equity (Book Value) | 80.04M |
| Book Value Per Share | 0.82 |
| Working Capital | 77.34M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$62.92 million and capital expenditures -$71,000, giving a free cash flow of -$62.99 million.
| Operating Cash Flow | -62.92M |
| Capital Expenditures | -71,000 |
| Free Cash Flow | -62.99M |
| FCF Per Share | -$0.64 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -41,395.26% |
| Pretax Margin | -39,540.53% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
aTyr Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -30.37% |
| Shareholder Yield | -30.37% |
| Earnings Yield | -79.88% |
| FCF Yield | -66.98% |
Analyst Forecast
The average price target for aTyr Pharma is $4.20, which is 337.59% higher than the current price. The consensus rating is "Hold".
| Price Target | $4.20 |
| Price Target Difference | 337.59% |
| Analyst Consensus | Hold |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 238.95% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 1, 2019. It was a reverse split with a ratio of 1:14.
| Last Split Date | Jul 1, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:14 |
Scores
aTyr Pharma has an Altman Z-Score of -1.84 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.84 |
| Piotroski F-Score | 2 |
